# Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda

> **NCT07408297** · PHASE2 · COMPLETED · sponsor: **Victoria Biomedical Research Institute** · enrollment: 1919 (actual)

## Conditions studied

- COVID -19
- SARS CoV 2 Infection

## Interventions

- **BIOLOGICAL:** Janssen Ad26COVS1
- **BIOLOGICAL:** Pfizer-BioNTech vaccine COVID-19 vaccine
- **BIOLOGICAL:** Inactivated Sinopharm or Sinovac COVID-19 vaccine

## Key facts

- **NCT ID:** NCT07408297
- **Lead sponsor:** Victoria Biomedical Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-18
- **Primary completion:** 2024-06-27
- **Final completion:** 2024-06-27
- **Target enrollment:** 1919 (ACTUAL)
- **Last updated:** 2026-02-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07408297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07408297, "Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07408297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*